
Guggenheim initiated coverage of MapLight Therapeutics (MPLT) with a Neutral rating and no price target The company’s Phase 2 readout in July confirmed ML-007C-MA’s mechanistic activity in schizophrenia but with
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc. | 7.25 | -6.84 | -48.55% |
| Name | Price | % Change | |
|---|---|---|---|
| $7.25 | -48.55% |

Guggenheim initiated coverage of MapLight Therapeutics (MPLT) with a Neutral rating and no price target The company’s Phase 2 readout in July confirmed ML-007C-MA’s mechanistic activity in schizophrenia but with

Guggenheim analyst Delma Caiati initiated coverage of MapLight Therapeutics (MPLT) with a Neutral rating. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

This filing relates to the offer and sale from time to time by the selling stockholders of up to 13.18M shares of common stock. The company is not selling any

Needham lowered the firm’s price target on MapLight Therapeutics (MPLT) to $43 from $45 and keeps a Buy rating on the shares. The firm is updating its model to reflect

MapLight Therapeutics (MPLT) announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing for gross proceeds of

“With positive Phase 2 data from ZEPHYR and continued progress in VISTA, we are focusing our efforts on advancing ML-007C-MA in both schizophrenia and ADP,” said Chris Kroeger, Co-Founder and

Raymond James lowered the firm’s price target on MapLight Therapeutics (MPLT) to $31 from $35 and keeps a Strong Buy rating on the shares. Following the ZEPHYR readout, the firm’s

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on MapLight Therapeutics (MPLT) to $21 from $24 and keeps a Buy rating on the shares. The firm said their Q2

MapLight Therapeutics, Inc. ( ($MPLT) ) has provided an update. On August 13, 2026, MapLight Therapeutics reported second-quarter 2026 results and business updates, highlighting its focus on central nervous system

UBS downgraded MapLight Therapeutics (MPLT) to Neutral from Buy with a price target of $13, down from $52. Recent Phase 2 schizophrenia results for ML-007 show low levels of efficacy
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Initiated | Oct 5, 2026 | ||||
| buy | Assigned | Aug 31, 2026 | ||||
| hold | Assigned | Aug 17, 2026 | ||||
| buy | Reiterated | Aug 14, 2026 | ||||
| buy | Reiterated | Aug 13, 2026 | ||||
| hold | Downgraded | Aug 11, 2026 | ||||
| buy | Reiterated | Jul 28, 2026 | ||||
| buy | Reiterated | Jul 28, 2026 | ||||
| buy | Reiterated | Jul 27, 2026 | ||||
| buy | Initiated | Jun 25, 2026 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.